immatics to receive support from Pfizer for its pivotal Phase III study (IMPRINT) with IMA901, a therapeutic vaccine for advanced renal cell cancer patients
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that…